* Aveo Pharmaceuticals Inc - announces completion of Tivo-3 study futility analysis with no changes to study protocol
* Aveo Pharmaceuticals Inc - study will continue as planned without modification.
* Aveo - analysis did not allow for early stopping due to efficacy to assure adequate follow-up for key secondary endpoint of overall survival
* Aveo - continues to expect Tivo-3 to read out in Q1 of 2018
* Aveo Pharmaceuticals Inc - expansion portion of trial is expected to enroll an additional 20 subjects Source text for Eikon: Further company coverage: